April  16, 2010 (FinancialWire) — Skinvisible, Inc. (OTCBB: SKVI) has entered into a research and development agreement with Women's Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Arizona.

The agreement is to develop a prescription formulation using Skinvisible's technology Invisicare, a patented polymer delivery system for topical dermatology and consumer goods products.

Skinvisible received a fee for the development of the product. Upon the successful completion, Skinvisible and Women's Choice will enter into a license agreement which includes a license fee paid in milestones plus on-going royalties based on product sales. Development is expected to be completed in the second quarter in anticipation of a third quarter launch.

Women's Choice Pharmaceuticals is an innovative specialty pharmaceutical company whose primary focus is to provide high quality prescription products to healthcare providers in the United States. The company provides technology based prescription products to the women's health market place, with their primary product portfolio consisting of three patent-protected products with market caps exceeding $500 million.

Skinvisible is focused on licensing products made with its patented technology, Invisicare worldwide to pharmaceutical, consumer goods and medical companies. License agreements include, upfront licensing fees, on-going royalties, along with the sale of Invisicare.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [prtnrshpsphs]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.